family with sequence similarity 86, member A pseudogeneGenealiases: []
Q-omics provides the consensus-scored FAM86JP profile across patient tissues and cancer cell-line models. FAM86JP expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, FAM86JP is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, FAM86JP RNA expression shows 17,625 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LIHC, HNSC, and ACC as cancer lineages where FAM86JP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM86JP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM86JP survival associations across molecular data types. FAM86JP RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM86JP RNA expression–survival associations across cancer types. High FAM86JP expression shows unfavorable associations in LIHC, MESO and LUAD, but favorable associations in UVM, KIRC and LUSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for FAM86JP RNA expression.
This table summarizes FAM86JP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for FAM86JP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM86JP shows lower tumor expression in THCA and higher tumor expression in HNSC, COAD, LUAD, LIHC and STAD. The HNSC box plot shows higher FAM86JP RNA expression in tumor versus normal tissue (log2 FC = +1.620, t-test p < 0.001).
This table shows molecular features associated with FAM86JP in patient tissues and cancer cell lines. In patient samples, FAM86JP shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
